Stockscreener 앱 받기
1.215
0.41%
0.005
전일 마감가:
$1.21
열려 있는:
$1.2
하루 거래량:
81,429
Relative Volume:
0.66
시가총액:
$14.51M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-2.1316
EPS:
-0.57
순현금흐름:
$-21.66M
1주 성능:
+4.74%
1개월 성능:
-2.02%
6개월 성능:
-68.52%
1년 성능:
-58.67%
1일 변동 폭
$1.1895
$1.23
1주일 범위
$1.1299
$1.36
52주 변동 폭
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
명칭
Nrx Pharmaceuticals Inc
전화
484-254-6134
주소
1201 ORANGE STREET, WILMINGTON
NRXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NRXP | 1.215 | 14.51M | 0 | -30.15M | -21.66M | -0.57 |
| VRTX | 449.72 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.00 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.52 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Po - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: NRx Pharmaceuticals projects profitability by 2025 - Investing.com UK
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer - BioSpace
NRx Pharmaceuticals Reports Progress in Drug Development - TipRanks
NRx Pharmaceuticals names Michael Abrams as new CFO - Investing.com
NRx Pharmaceuticals Names Biotech Veteran Michael Abrams as New CFO to Drive Growth | NRXP Stock News - StockTitan
NRXPNRX Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NRX Pharmaceuticals Inc (NRXP) Quarterly 10-Q Report - Quartz
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update - Yahoo Finance
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NRx Pharmaceuticals delays Q3 results call to November 18 By Investing.com - Investing.com Canada
NRx Pharmaceuticals delays Q3 results call to November 18 - Investing.com
NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024 - XM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 - Yahoo Finance
NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Thursday - Defense World
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 - BioSpace
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update L - GuruFocus.com
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule - GlobeNewswire
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq th - GuruFocus.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Unde - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarte - GuruFocus.com
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2 - GuruFocus.com
NRx Pharmaceuticals, Inc. and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - Marketscreener.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE - GlobeNewswire
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan
EF Hutton Acquisition Co. I Upgrades NRx Pharmaceuticals (NASDAQ:NRXP) to Strong-Buy - Defense World
Can Nrx combination unlock NMDA’s oomph in akathisia? - BioWorld Online
EF Hutton sets stock target on NRx Pharma, cites suicide prevention - Investing.com India
NRx started at buy by EF Hutton, cites suicide prevention focus - MSN
NRx started at buy by EF Hutton, cites suicide prevention focus (NASDAQ:NRXP) - Seeking Alpha
NRx Pharmaceuticals secures additional $5 million funding By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals secures additional $5 million funding - Investing.com India
NRx Pharmaceuticals announces CEO resignation and stockholder votes - Investing.com
NRx Pharmaceuticals announces CEO resignation and stockholder votes By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions - Yahoo Finance
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
NRXP stock touches 52-week low at $1.33 amid market challenges - Investing.com
NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding from Streeterville Capital, LLC - Marketscreener.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
HOPE Therapeutics and NRx Pharmaceuticals to Acquire a Premier West Coast Interventional Psychiatric Clinic - citybiz
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic - cnhinews.com
NRXP stock touches 52-week low at $1.59 amid market challenges By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access - MyChesCo
NRXP stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Nrx Pharmaceuticals Inc (NRXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):